Economist Intelligence Unit (EIU) Report launched today reveals only one in three rare disease patients receives the best-available, evidence-based care. Less than a third of surveyed healthcare...

Today, the first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have commenced in Australia The first human trials using the University of Queensland’s (UQ) COVID-19...

Applications are now open for the 2021 CSL Centenary Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic...

Plasma-derived therapeutic with potential to treat serious complications of COVID-19. MELBOURNE, AUSTRALIA – CSL Behring Australia, a subsidiary of CSL Limited, today announced that it will...

To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing. Anthony Farina – Chief Communications Officer, CSL Limited 18 Mar 2020 As...

CSL Limited's statement on Coronavirus Coronavirus is quite different to influenza virus so it is not a core area of focus for CSL or Seqirus. However, we have investigated possible adjacencies in...

Forbes Magazine named CSL among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six different categories, are based on an independent survey of more than...

The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne,...

CSL statement in response to media reports on case against Joseph Chiao The Sydney Morning Herald on 18 October 2019 reported that former CSL employee Dr Joseph Chiao ‘stole patient data’. CSL...

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

Two Australian scientists have each been awarded AUD$1.25 million CSL Centenary Fellowships over five years to improve treatments for two of the world’s biggest health challenges: malaria and...

Major landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbourne’s place as a world-class research destination MELBOURNE,...

MELBOURNE, Australia - CSL today announced its continued partnership with the National Youth Science Forum (NYSF) signing a new three-year agreement in support of programs that encourage life-long...

The Honourable John Brumby AO today formally opened the new ‘Nancy Millis’ building, an expansion of the Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne,...

CSL spotlights developments in cell-based vaccine technology at Australian Research and Development briefing CSL Limited (ASX:CSL; USOTC:CSLLY) subsidiary Seqirus, today presented new real-world...

Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into why so many people die from infection following stroke and how we...

$2.5 Million Funding Available to Australian Biomedical Researchers Melbourne, Australia: 01.06.2018 - Australia’s best and brightest biomedical researchers are invited to apply for one of two...

CSL Limited today announced a revised profit outlook for fiscal 2018. CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a revised profit outlook for fiscal 2018. The Company now expects net...

Dr Brian McNamee AO and Mr Abbas Hussain have been appointed as independent Non-Executive Directors, effective 14 February 2018. CSL (ASX:CSL; USOTC:CSLLY) today announced that Dr Brian McNamee AO...

CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian governments, to continue to provide the community with a world-class and...

CSL today officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben...

The study will be the largest ever undertaken by CSL, and will enroll more than 17,000 patients from approximately 1,000 sites around the world. Jemimah Pentland 05 Dec 2017 Global biotherapeutics...

Two Australian scientists have each been awarded an AUD$1.25 million, five-year, CSL Centenary Fellowship to further research into gentler, more effective cancer diagnostics and, to advance...

Australia’s biomedical researchers are invited to apply for one of two CSL Centenary Fellowships each worth $1.25million over five years in support of discovery and translational medical...

An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the progression of Diabetic Kidney Disease (DKD) in laboratory studies of type...